Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice (Q51005810)

26 March 2018

title

Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice (English)

1 reference

26 March 2018

1 reference

Faramarz Dobakhti

2

0 references

author name string

Soheila Ajdary

1

1 reference

26 March 2018

Mohammad Taghikhani

3

1 reference

26 March 2018

Farhad Riazi-Rad

4

1 reference

26 March 2018

Shahnaz Rafiei

5

1 reference

26 March 2018

Morteza Rafiee-Tehrani

6

1 reference

26 March 2018

language of work or name

English

0 references

publication date

11 April 2007

1 reference

26 March 2018

published in

Vaccine

1 reference

26 March 2018

volume

25

1 reference

26 March 2018

issue

23

1 reference

26 March 2018

page(s)

4595-4601

1 reference

26 March 2018

Modern vaccines. Mycobacterial diseases

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Needle-free vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

NALT- versus Peyer's-patch-mediated mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Controlled release microparticles for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Oral vaccination of mice with lipid-encapsulated Mycobacterium bovis BCG: anatomical sites of bacterial replication and immune activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Oral vaccination of animals with antigens encapsulated in alginate microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Multiple intestinal 'loops' provide an in vivo model to analyse multiple mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Stabilizing effects of calcium alginate microspheres on Mycobacterium bovis BCG intended for oral vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Mucosal delivery of vaccine antigens and its advantages in pediatrics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Induction of pulmonary immunity in cattle by oral administration of ovalbumin in alginate microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

T cell response to Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Physically crosslinked alginate/N,O-carboxymethyl chitosan hydrogels with calcium for oral delivery of protein drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Calcium alginate microparticles for oral administration: II. Effect of formulation factors on drug release and drug entrapment efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

A single strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) grown in two different media evokes distinct humoral immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Mice fed lipid-encapsulated Mycobacterium bovis BCG are protected against aerosol challenge with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Effect of oral vaccination of cattle with lipid-formulated BCG on immune responses and protection against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Production of 5-15 microns diameter alginate-polylysine microcapsules by an air-atomization technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Production of BCG alginate-PLL microcapsules by emulsification/internal gelation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.039

10.1016/J.VACCINE.2007.03.039

7 January 2021

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018